^
BIOMARKER:

MYC rearrangement + BCL6 rearrangement

i
Other names: BCL6, BCL5, BCL6A, LAZ3, ZBTB27, ZNF51, B-cell CLL/lymphoma 6, MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Entrez ID:
2ms
The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements was low in DLBCLs, and no significant correlation between gene abnormality and protein overexpression was shown. The correct diagnosis of DHL depends on molecular genetic detection.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
TP53 mutation • BCL2 expression • MYC expression • MYC overexpression • MYC rearrangement • MYC rearrangement + BCL6 rearrangement • BCL2 rearrangement • BCL6 rearrangement • TP53 expression
4ms
DH/TH status and DH status alone were associated with poorer OS and DSS (both p<0,05) among all pcDLBCLs, without reaching statistical significance in pcDLBCL-LT and pcDLBCL-NOS groups. In conclusion, MYC, BCL2 and BCL6 cytogenetical testing could be useful in identifying a putative subset of more aggressive pcDLBCLs, although this observation has to be confirmed by further studies.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • MYC rearrangement • MYC rearrangement + BCL6 rearrangement • MYC translocation • BCL2 rearrangement • BCL6 rearrangement
7ms
Conclusion The classification of primary cutaneous BCL displaying diffuse pattern and predominantly large cell morphology can be challenging. Correlation with clinical presentation, staging, histological features, immunohistochemistry and molecular analysis is crucial to reach the diagnosis that will allow prognostication and therapy.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • IRF4 (Interferon regulatory factor 4)
|
MYC rearrangement + BCL6 rearrangement • BCL6 rearrangement
7ms
Conclusion The classification of primary cutaneous BCL displaying diffuse pattern and predominantly large cell morphology can be challenging. Correlation with clinical presentation, staging, histological features, immunohistochemistry and molecular analysis is crucial to reach the diagnosis that will allow prognostication and therapy.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • IRF4 (Interferon regulatory factor 4)
|
MYC rearrangement + BCL6 rearrangement • BCL6 rearrangement
7ms
Conclusion The classification of primary cutaneous BCL displaying diffuse pattern and predominantly large cell morphology can be challenging. Correlation with clinical presentation, staging, histological features, immunohistochemistry and molecular analysis is crucial to reach the diagnosis that will allow prognostication and therapy.
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • IRF4 (Interferon regulatory factor 4)
|
MYC rearrangement + BCL6 rearrangement • BCL6 rearrangement
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our